Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) Analogue

Stanhope, R; Pringle, P. J.; Brook, C. G. D.

doi:10.1111/j.1651-2227.1988.tb10694.x

Cited by 56 publications

(29 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the latter study, GH levels were determined with the same assay in the same laboratory. We previously reported that GH levels significantly decreased during 3 months of GnRHa treatment (16), similar to reports in patients with precocious puberty treated with GnRHa (39)(40)(41). This is probably partly due to diminution of sex steroids (42).…”

Section: Start Of Gnrha Treatment (Nz41)supporting

confidence: 69%

Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels

Kaay¹,

Bakker²,

Hulst³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: GnRH analogue (GnRHa) combined with GH treatment has been proposed to increase adult height. Effect on metabolic profile and GH, IGF1, and IGFBP3 levels in short small for gestational age (SGA) children is unknown. Objective: To assess fat mass and lean body mass SDS, percentage trunk fat, blood pressure (BP), insulin sensitivity (Si), b-cell function (disposition index, DI), lipid profile, and GH, IGF1, and IGFBP3 levels during 2 years of combined treatment. Subjects: Forty-one pubertal short SGA children with a mean (GS.D.) age of 12.1 (G1.0) years. Design: Children received 3.75 mg of leuprolide acetate depot subcutaneously every 4 weeks, and they were randomly assigned to receive 1 mg (group A) or 2 mg (group B) of GH/m 2 per day. Results: Percentage trunk fat increased in both groups, but to a lower extent in group B. Lean body mass SDS increased only in group B. Changes in BP, Si, DI, and lipids were similar in both groups. Si significantly decreased, but DI remained unchanged. Lipids remained normal. GH and IGF1 levels were significantly higher in group B. Conclusion: Our study is the first to report that 2 years of combined treatment with a GnRHa and either 1 or 2 mg GH/m 2 per day does not adversely affect body composition and metabolic profile of short SGA children who come under medical attention at the onset of puberty. There was a dose-dependent effect on fat mass SDS height , percentage trunk fat, lean body mass SDS height , and GH and IGF1 levels in favor of treatment with GnRHa and the higher GH dose of 2 mg/m 2 per day.

show abstract

Section: Start Of Gnrha Treatment (Nz41)supporting

confidence: 69%

Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels

Kaay¹,

Bakker²,

Hulst³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Some studies in children with central precocious puberty found lower stimulated and spontaneous growth hormone levels during GnRH analogue treatment, others could not replicate these findings (DiMartino-Nardi et al, 1991;Sklar et al, 1991;Stanhope et al, 1988). Poor growth might also be directly related to reduced sex steroid levels or growth plate senescence by prior estrogen exposure (Savendahl, 2005;Weise et al, 2004).…”

Section: Effects Of Gnrh Analogue Treatment On Growth and The Gh-igf-mentioning

confidence: 85%

GH-IGF-IGFBP Axis and Metabolic Profile in Short Children Born Small for Gestational Age

Kaay¹,

Hokken-Koelega²

2011

Update on Mechanisms of Hormone Action - Focus on Metabolism, Growth and Reproduction

View full text Add to dashboard Cite

“…Basal LH values are not as sensitive as the peak values, as they are only moderately reduced [24]or do not change [11, 25, 26]during GnRHa treatment. The sensitivity of the stimulation test is good even if only one blood sample between 30 and 60 min after GnRH administration is used (instead of several samples in the standard procedure), according to Cavallo et al [23].…”

Section: Discussionmentioning

confidence: 99%

“…Clinical escape during GnRH analogue treatment, associated with noncompliance, has been reported [7], but there are now several publications demonstrating a good clinical suppressive effect of both short acting and depot GnRH agonists, when compliance has been assured [7, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]. …”

Section: Discussionmentioning

confidence: 99%

Suppression of Puberty in Girls with Short-Acting Intranasal versus Subcutaneous Depot GnRH Agonist

Tuvemo

Gustafsson

Proos³

2002

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aim: Central precocious puberty (CPP) is more common in females than in males. During the last few decades a new group of patients with CPP has been seen frequently in Northern Europe, namely children adopted from developing countries. GnRH analogue preparations, administered either as intranasal spray or as depot preparations, are the drugs of choice for inhibiting the release of gonadotropins. The aim of this study was to compare the effect of buserelin given by intranasal spray with that of the same compound given as a subcutaneous depot preparation. Methods: The study group comprised 46 pubertal girls below the age of 9.5 years, adopted from a developing country. During the first 2 years, the treatment used was buserelin acetate 300 µg 6 times daily as a nasal spray. During the third year the treatment was changed to Suprefact Depot, 6.3 mg, given as a subcutaneous implant every 8 weeks. Half of the girls were randomized to growth hormone treatment in addition to the pubertal inhibition. Results: GnRH provocation tests after 6 weeks, 1 year and 2 years of treatment with intranasal GnRH analogue showed suppression of gonadotropin secretion except in 1 case of noncompliance. During the third year, when the long-acting depot preparation was used, suppression was more pronounced. The peak LH response, especially, was considerably lower than during treatment with the nasal spray preparation. In all cases the clinical inhibition of puberty was adequate both during the first two years and during the third year. Conclusion: Even though the clinical suppression of puberty was adequate with both modes of administration, the effect of the depot preparation, in this study Suprefact Depot, was more pronounced in terms of gonadotropin suppression and less dependent on patient compliance.

show abstract

Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) Analogue

Cited by 56 publications

References 24 publications

Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels

Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels

GH-IGF-IGFBP Axis and Metabolic Profile in Short Children Born Small for Gestational Age

Suppression of Puberty in Girls with Short-Acting Intranasal versus Subcutaneous Depot GnRH Agonist

Contact Info

Product

Resources

About